HEALTHMEDPAGE TODAY
LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors
A phase III trial of an investigational LSD-based pill (DT120) showed it met primary and key secondary endpoints in treating adults with major depressive disorder, according to Definium Therapeutics. The results suggest potential efficacy for the treatment of depression.
Related Signal
Adjacent reporting
- Definium’s shares surge 55% after LSD-based depression pill delivers strong results
- STAT+: Definium LSD therapy helped patients with major depression in late-stage trial
- STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
- Controversial drug delivered rapid relief for severe depression in just hours
- STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
- New depression treatment targets the immune system instead of the brain